SCHEMBL2793473

SCHEMBL2793473

COc1ccc(C(O)(C(=O)O)c2ccccc2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 2/20 0.58
KMT2A Q03164 2/20 0.56
MEN1 O00255 1/20 0.56
ALDH1A1 P00352 2/20 0.53
CES2 O00748 1/20 0.52
CES1 P23141 1/20 0.52
KIF11 P52732 5/20 0.50
CYP2D6 P10635 1/20 0.50
HIF1A Q16665 1/20 0.50
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA4 P22748 1/20 0.46
KDM4E B2RXH2 1/20 0.46
GAA P10253 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
KCNH2 Q12809 1/20 0.46
PTGS2 P35354 1/20 0.46
F10 P00742 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2795435 0.94 CYP2C9 (0.55) CYP2C9KMT2AMEN1ALDH1A1CES2
Bromomethane SCHEMBL3169542 0.91 CYP2C9 (0.52) CYP2C9KMT2AMEN1ALDH1A1CES2
SCHEMBL28711201 0.89 KMT2A (0.60) KMT2AMEN1ALDH1A1CES2CES1
Benzylic Acid SCHEMBL11870645 0.86 CYP2C9 (0.63) CYP2C9KMT2AMEN1ALDH1A1CES1
SCHEMBL2319756 0.86 KMT2A (0.54) KMT2AMEN1ALDH1A1CES2CES1
SCHEMBL14166571 0.84 CYP2C9 (0.49) CYP2C9KMT2AMEN1ALDH1A1CES2
SCHEMBL6203510 0.84 CES1 (0.56) KMT2AMEN1ALDH1A1CES2CES1
SCHEMBL6045338 0.83 KCNN4 (0.55) KMT2AMEN1ALDH1A1CES2CES1
SCHEMBL23828851 0.83 KMT2A (0.51) KMT2AMEN1ALDH1A1CES2CES1
Benzylic Acid SCHEMBL7066 0.82 CYP2C9 (0.74) CYP2C9KMT2AALDH1A1CYP2D6HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115108901-A Synthetic method of alpha-hydroxycarboxylic acid compound 四川大学 2022-09-27 CN disclosed
US-8084463-B2 Quinuclidine derivatives and their use as muscarinic M3 receptor antagonists NOVARTIS AG (CH) 2011-12-27 US disclosed
US-20100249451-A1 PROCESS FOR THE PREPARATION OF SUBSTITUTED BENZILIC ACID FROM SUBSTITUTED BENZILS COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2010-09-30 US disclosed
EP-1811999-B1 QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 RECEPTOR ANTAGONISTS NOVARTIS AG (CH) 2010-09-15 EP disclosed
EP-2206499-A1 QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 RECEPTOR ANTAGONISTS Novartis AG (CH) 2010-07-14 EP disclosed
US-20100168132-A1 QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 RECEPTOR ANTAGONISTS PRESS NEIL JOHN 2010-07-01 US disclosed
US-7723356-B2 Quinuclidine derivatives and their use as muscarinic m3 receptor antagonists NOVARTIS AG (CH) 2010-05-25 US disclosed
US-20090048281-A1 (R)-3-(2-Cyclohexyl-2-hydroxy-2-phenyl-acetoxy)-1-(isoxazol-3-ylcarbamoylmethyl)-1-azonia-bicyclo[2.2.2] octane, useful for treating inflammatory or obstructive airways diseases NOVARTIS AG (CH) 2009-02-19 US disclosed
EP-1811999-A1 QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 RECEPTOR ANTAGONISTS Novartis AG (CH) 2007-08-01 EP disclosed
WO-2006048225-A1 QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 RECEPTOR ANTAGONISTS NOVARTIS AG (CH) 2006-05-11 WO disclosed
US-4126468-A Radiation sensitive compositions of quaternary ammonium salt and carboxylic acid sensitizer VICKERS LIMITED (GB) 1978-11-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249451-A1 PROCESS FOR THE PREPARATION OF SUBSTITUTED BENZILIC ACID FROM SUBSTITUTED BENZILS KCNC1, HRH2, SMARCC2 CYP2C9 400/4885KMT2A 320/4885MEN1 3333/4885
US-20090048281-A1 (R)-3-(2-Cyclohexyl-2-hydroxy-2-phenyl-acetoxy)-1-(isoxazol-3-ylcarbamoylmethyl)-1-azonia-bicyclo[2.2.2] octane, useful for treating inflammatory or obstructive airways diseases CHRM3, CHRM2, CHRM1 CYP2C9 1533/4885KMT2A 2413/4885MEN1 4480/4885
US-20100168132-A1 QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 RECEPTOR ANTAGONISTS CHRM3, CHRM2, CHRM1 CYP2C9 1459/4885KMT2A 1968/4885MEN1 2183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.